Umibecestat: Clinical Trials

3 trials of Umibecestat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed. 3 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Terminated 2, Completed 1
Phase 32Terminated 2

Follow Umibecestat: new trials by email Literature Review of Umibecestat trials Research Report on Umibecestat

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
CNP520 50mg, CNP520 15mg, Matching placebo - Alzheimers Disease
Phase 2 / Phase 3TerminatedNovartis Pharmaceuticals11452017-08-032021-08-05
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
CAD106 Immunotherapy, Placebo to CAD106, CNP520 - Alzheimers Disease
Phase 2 / Phase 3TerminatedNovartis Pharmaceuticals4802015-11-302021-07-08
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
CNP520, Placebo - Alzheimer's Disease
Phase 2CompletedNovartis Pharmaceuticals1242015-08-102017-08-11

Conditions studied

Alzheimer Disease (3)  ·  Plaque, Amyloid (1)

Sponsors

Novartis Pharmaceuticals (3)

Countries

Belgium (3)  ·  Germany (3)  ·  Netherlands (3)  ·  United Kingdom (3)  ·  United States (3)  ·  Australia (2)  ·  Canada (2)  ·  Finland (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Argentina (1)  ·  Chile (1)  ·  China (1)  ·  France (1)  ·  Iceland (1)

NIH funding

1UF1AG046150-01 (1), 2015 (1), 2016 (1)